Morphine-6-glucuronide, an active morphine metabolite for the potential treatment of post-operative pain.
Morphine-6-glucuronide (M6G) is an active metabolite of morphine that is being developed by CeNeS Pharmaceuticals as an alternative to morphine (the most commonly used opioid) for the management of postoperative pain. M6G is currently undergoing phase III clinical trials in patients with postoperative pain.
Joshi
Girish P
GP
University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9068, USA. girish.joshi@utsouthwestern.edu
D000701:Analgesics, Opioid / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009022:Morphine Derivatives / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D010149:Postoperative Pain / Q000188:drug therapy*; D010330:Patents as Topic; D013329:Structure-Activity Relationship
D000701:Analgesics, Opioid; D009022:Morphine Derivatives; C035349:morphine-6-glucuronide